Skip to main content
. 2012 Mar 1;12(3):1–64.

Table 3: Randomized Controlled Trials of the Pneumococcal Vaccine in Patients with Respiratory Illness*.

Author, Year Patients Population Comparison Outcomes/Objectives
Leech et al, 1987 (41) 189 COPD IF + PN Vaccine vs. PN+Placebo

  • incidence of pneumonia

  • antibody response

  • mortality
Davis et al, 1987 (42) 103 COPD 14-valent vaccine vs. placebo

  • incidence of pneumonia

  • mortality
Steentoft et al, 2006 (43) 49
In 4 groups (Steroid +/- vaccine/placebo)		 COPD Effect of steroid on antibody levels Clinical variables

  • antibody response

  • incidence of pneumonia

  • exacerbation

  • hospital admission

  • lung function
Meyer et al, 2006 (44) 30 (3 arms) IM vs. alveolar ventilation vs. bronchial ventilation COPD Comparison between 3 arms

  • antibody response

  • adverse events
Alfagemeet al, 2006 (45) 596 COPD 23-valent vaccine vs. no vaccine

  • CAP diagnosed by chest x-ray (mean of 979 days)

  • mortality
Ya Tseimakh et al, 2006 (46)     Abstract  
Teramotoet al, 2007 (47)     Abstract  
Furumoto et al, 2008 (48) 167 Chronic lung disease Group 1: IF + PN
Group 2: IF

  • incidence of pneumonia and acute exacerbation
Dransfield et al, 2009 (49) 120 COPD (Moderate to severe) 7-valent vaccine vs. 23-valent

  • immune response
*

Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; IF, influenza vaccine; PN, pneumococcal vaccine.